COVID-19 Immunologic Antiviral Therapy With Omalizumab (CIAO)-a Randomized Controlled Clinical Trial.
Michelle LeLauren KhouryYang LuConnor ProstyMaxime CormierMatthew Pellan ChengRobert FowlerSrinivas MurthyJennifer L Y TsangMoshe Ben-ShoshanElham RahmeShirin GolchiNandini DendukuriTodd C LeeElena NetchiporoukPublished in: Open forum infectious diseases (2024)
These results suggest that omalizumab could prove protective against death and mechanical ventilation in hospitalized patients with COVID-19. This study could also support the development of a phase III trial program investigating the antiviral and anti-inflammatory effect of omalizumab for severe respiratory viral illnesses requiring hospital admission. ClinicalTrials.gov ID: NCT04720612.
Keyphrases
- phase iii
- mechanical ventilation
- open label
- clinical trial
- sars cov
- acute respiratory distress syndrome
- phase ii
- anti inflammatory
- intensive care unit
- coronavirus disease
- double blind
- placebo controlled
- emergency department
- quality improvement
- respiratory failure
- early onset
- study protocol
- stem cells
- extracorporeal membrane oxygenation
- mesenchymal stem cells
- acute care